Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054098 | 0.89 | PTGDR2 (0.56) | PTGDR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1055326 | 0.86 | PTGDR2 (0.75) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL15134863 | 0.84 | PTGDR2 (0.52) | PTGDR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL139547 | 0.81 | PTGDR2 (0.63) | PTGDR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1057389 | 0.78 | PTGDR2 (0.81) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1055322 | 0.77 | PTGDR2 (0.73) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3627264 | 0.77 | PTGDR2 (0.73) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3629694 | 0.76 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1060068 | 0.76 | RXRA (0.46) | PTGDR2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1060296 | 0.75 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PSEN1 3725/4885PSEN2 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.